Author:
Galani Vasiliki,Varouktsi Anna,Papadatos Stamatis S.,Mitselou Antigoni,Sainis Ioannis,Constantopoulos Stavros,Dalavanga Yotanna
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference103 articles.
1. Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT et al (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 133(8):1317–1331
2. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA et al (2012) Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 227(1):44–58
3. Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL (2018) Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med 142(6):753–760
4. Galani V, Constantopoulos S, Manda-Stachouli C, Frangou-Lazaridis M, Mavridis A, Vassiliou M et al (2002) Additional proteins in BAL fluid of Metsovites environmentally exposed to asbestos: more evidence of “protection” against neoplasia? Chest 121(1):273–278
5. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C et al (2010) Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 107(28):12611–12616
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献